Evidence of Antidepressant Harm that the FDA Sought to Suppress from FDA’s Public Advisory Committee Meeting on February 2 Evidence was presented on February 2 at AHRP’s press briefing by the following scientists: David Healy, MD, Director of the North Wales Department of Psychological Medicine and Visiting Professor, University of…
Selling Sickness: Pharma Industry Turning Us All Into Patients Mon, 12 Sep 2005 Related Link: Selling Sickness Prologue Selling Sickness: How the World’s Pharmaceutical Companies Are Turning Us All Into Patients, by Ray Moynihan, an international health journalist, and Alan Cassels, a pharmaceutical policy researcher, is likely to become a…
Cong Hinchey PRESS CONFERENCE Re: Drug Co. Influence on FDA Sat, 10 Jul 2004 New York Congressman Maurice Hinchey (House Appropriations Committee) is holding a press conference on Tuesday, July 13, 2004, at 10:30 AM to address issues of concern about undue influence by drug manufacturers on FDA policy and…
Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now Wed, 4 Feb 2004 On February 2, more than 60 families and children from all across America testified at a public FDA advisory committee hearing describing (in 2 minutes) how their children suffered drug-induced harm after being prescribed an…
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx…
Antidepressant Controversy: Media Conflicts of Interest – New York Times Thu, 25 Mar 2004 FDA’s advisory warning about antidepressant drugs received wide press coverage nationally. But few in the national media mentioned conflicts of interest as the obstacle to disclosure of evidence showing these drugs’ adverse effects. Among the few…
Psychiatry and Preschoolers Tue, 1 Jul 2003 There was a time that doctors followed the precautionary “do no harm” principle when prescribing drugs. But the practice of medicine has changed radically as physicians have increasingly become financially tied to the pharmaceutical industry. Among psychiatrists it is difficult to find one…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
Three Questionable FDA policies: drug factory inspection rules/ clinical trials/ Paxil ads Thu, 22 Aug 2002 Three news items highlight questionable FDA policies that are in conflict with consumer health interests. 1) Poor quality control standards in American drug and vaccine manufacturing plants is a disgrace. The Associated Press reports…
27 April 2004 Background Information Representative, U.S. The Honorable Mr. Joe Barton, United States House of Representatives. Washington DC. Representative, U.S. The Honorable Mr. James Greenwood, United States House of Representatives, Washington DC. Number of US Citizens at Risk to SSRIs This letter is to advise you that there is…
$95 billion a year spent on medical research in US – JAMA Fri, 23 Sep 2005 A special issue of the Journal of the American Medical Association, JAMA, focuses on medical research spending and findings. A study that examined US spending for medical research—$95 billion approaching $100 billion–57% is spent…
Mosholder Suppressed Report Posted/ Bush Moves to Block Medical Suits – NYT Mon, 26 Jul 2004 The New York Times reports that the Bush administration is actively blocking individual citizens who have been seriously harmed from drug-related hazards from suing drug manufacturers. The administration argues that “if a local judge…
